Twist Bioscience (NASDAQ: TWST) furnishes fiscal Q1 2026 results press release

Rhea-AI Filing Summary

Twist Bioscience Corporation filed a current report to note that it issued a press release announcing its financial results for the quarter ended December 31, 2025. The press release, titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results”, is furnished as Exhibit 99.1.

The company states that the information in this report, including Exhibit 99.1, is being furnished rather than filed under the Securities Exchange Act of 1934 and is not automatically incorporated by reference into Securities Act registration statements unless specifically referenced.

FALSE000158128000015812802026-02-022026-02-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

February 2, 2026

Twist Bioscience Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-38720

46-2058888

(State or other jurisdiction of incorporation)

(Commission File Number)

(I. R. S. Employer Identification No.)

681 Gateway Boulevard

South San Francisco, CA 94080

(Address of principal executive offices, including ZIP code)

(800) 719-0671

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

TWST

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02Results of Operations and Financial Condition.

On February 2, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press release dated February 2, 2026 titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results”
104						Cover Page Interactive Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 2, 2026			Twist Bioscience Corporation
			/s/ Judy Yan
			Judy Yan
			Assistant General Counsel and Assistant Secretary

FAQ

What did Twist Bioscience (TWST) disclose in its latest SEC filing?

Twist Bioscience disclosed that it issued a press release announcing financial results for the quarter ended December 31, 2025. The release, furnished as Exhibit 99.1, is titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results.”

Which period do Twist Bioscience’s newly announced results cover?

The newly announced results cover Twist Bioscience’s financial performance for the quarter ended December 31, 2025. This period corresponds to the company’s fiscal first quarter 2026, as reflected in the title of Exhibit 99.1 attached to the current report.

Where can investors find Twist Bioscience’s fiscal first quarter 2026 results?

Investors can find Twist Bioscience’s fiscal first quarter 2026 results in the press release furnished as Exhibit 99.1 to the current report. The exhibit is titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results.”

Is Twist Bioscience’s fiscal Q1 2026 press release considered filed with the SEC?

No, Twist Bioscience specifies that the information in Item 2.02, including Exhibit 99.1, is being furnished rather than filed. It is not subject to Section 18 liabilities and is not incorporated into Securities Act filings unless specifically referenced.

What exhibits did Twist Bioscience include with this current report?

Twist Bioscience included two exhibits: Exhibit 99.1, a press release titled “Twist Bioscience Reports Fiscal First Quarter 2026 Financial Results,” and Exhibit 104, the Cover Page Interactive Data File formatted as Inline XBRL.

Who signed Twist Bioscience’s current report related to the fiscal Q1 2026 results?

The current report was signed on behalf of Twist Bioscience by Judy Yan, who is identified as Assistant General Counsel and Assistant Secretary. The signature block shows the report dated February 2, 2026 for Twist Bioscience Corporation.